New Zealand agrees to fund Iressa but amends Tarceva use

5 July 2012

New Zealand’s pharmaceutical management agency PHARMAC has approved the proposal to fund AstraZeneca’s (LSE: AZN) Iressa (gefitinib) and to amend the Special Authority criteria applying to Roche’s (ROG: SIX) Tarceva (erlotinib). This was the subject of a consultation letter dated May 31, 2012.

In summary, the effect of the decision is that:

•  from August 1, 2012, Iressa will be funded as a first line treatment for patients with locally advanced, or metastatic, unresectable, non-squamous non-small cell lung cancer (NSCLC) expressing activating mutations in Epidermal Growth Factor Receptor (EGFR) tyrosine kinase.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical